S 
Stryker SYK · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
325.73
-0.04%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$25.12bn
FY2016FY2025
Net income
$3.25bn
FY2016FY2025
Free cash flow
$4.28bn
FY2016FY2025
Shareholders' equity
$22.42bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.12bn | $22.59bn | $20.50bn | $18.45bn | $17.11bn | $14.35bn | $14.88bn | $13.60bn | $12.44bn | $11.32bn |
| Gross profit | $16.07bn | $13.98bn | $12.49bn | $11.04bn | $10.71bn | $8.75bn | $9.38bn | $8.60bn | $7.90bn | $7.25bn |
| Research and development | $1.58bn | $1.41bn | $1.29bn | $1.23bn | $1.13bn | $905.0m | $971.0m | $862.0m | $787.0m | $715.0m |
| Operating income | $4.89bn | $5.06bn | $4.28bn | $3.73bn | $3.76bn | $3.03bn | $3.39bn | $3.10bn | $2.77bn | $2.58bn |
| Net income | $3.25bn | $2.99bn | $3.17bn | $2.36bn | $1.99bn | $1.60bn | $2.08bn | $3.55bn | $1.02bn | $1.65bn |
| Diluted earnings per share | 8.40 | 7.75 | 8.24 | 6.17 | 5.21 | 4.19 | 5.48 | 9.35 | 2.68 | 4.34 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $47.84bn | $42.97bn | $39.91bn | $36.88bn | $34.63bn | $34.33bn | $30.17bn | $27.23bn | $22.18bn | $20.43bn |
| Cash and short-term investments | $4.10bn | $4.40bn | $3.05bn | $1.93bn | $3.02bn | $3.02bn | $4.42bn | $3.70bn | $2.79bn | $3.38bn |
| Total liabilities | $25.42bn | $22.34bn | $21.32bn | $20.27bn | $19.75bn | $21.25bn | $17.36bn | $15.50bn | $12.19bn | $10.88bn |
| Debt | $15.86bn | $13.60bn | $12.99bn | $13.05bn | $12.48bn | $13.99bn | $11.09bn | $9.86bn | $7.22bn | $6.91bn |
| Shareholders' equity | $22.42bn | $20.63bn | $18.59bn | $16.62bn | $14.88bn | $13.08bn | $12.81bn | $11.73bn | $9.99bn | $9.55bn |
| Shares outstanding | 387m | 386m | 384m | 382m | 383m | 381m | 380m | 380m | 381m | 379m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $5.04bn | $4.24bn | $3.71bn | $2.62bn | $3.26bn | $3.28bn | $2.19bn | $2.61bn | $1.56bn | $1.92bn |
| Capital spending | −$761.0m | −$755.0m | −$575.0m | −$588.0m | −$525.0m | −$487.0m | −$649.0m | −$572.0m | −$598.0m | −$490.0m |
| Free cash flow | $4.28bn | $3.49bn | $3.14bn | $2.04bn | $2.74bn | $2.79bn | $1.54bn | $2.04bn | $961.0m | $1.43bn |
| Dividends paid | −$1.28bn | −$1.22bn | −$1.14bn | −$1.05bn | −$950.0m | −$863.0m | −$778.0m | −$703.0m | −$636.0m | −$568.0m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.59bn | $6.02bn | $7.17bn | $6.06bn | $6.02bn | $5.87bn | $6.44bn | $5.49bn |
| Gross profit | $4.50bn | $3.81bn | $4.68bn | $3.85bn | $3.75bn | $3.68bn | $3.99bn | $3.39bn |
| Operating income | $1.66bn | $936.0m | $1.96bn | $1.14bn | $1.36bn | $764.0m | $1.66bn | $1.21bn |
| Net income | $1.28bn | $745.0m | $849.0m | $859.0m | $884.0m | $654.0m | $546.0m | $834.0m |
| Diluted earnings per share | 3.31 | 1.93 | 2.20 | 2.22 | 2.29 | 1.69 | 1.41 | 2.16 |
| Cash from operations | $1.26bn | $581.0m | $2.14bn | $1.54bn | $1.11bn | $250.0m | $1.93bn | $1.47bn |
| Capital spending | −$202.0m | −$166.0m | −$268.0m | −$187.0m | −$183.0m | −$123.0m | −$266.0m | −$170.0m |
| Free cash flow | $1.06bn | $415.0m | $1.88bn | $1.35bn | $928.0m | $127.0m | $1.67bn | $1.30bn |
| Total assets | $47.93bn | $46.29bn | $47.84bn | $47.06bn | $46.33bn | $46.01bn | $42.97bn | $43.83bn |
| Cash and short-term investments | $3.48bn | $2.96bn | $4.10bn | $3.34bn | $2.46bn | $2.41bn | $4.49bn | $4.68bn |
| Debt | $14.94bn | $14.88bn | $16.01bn | $16.76bn | $16.74bn | $16.94bn | $13.74bn | $15.63bn |
| Shareholders' equity | $23.99bn | $22.98bn | $22.42bn | $21.79bn | $21.19bn | $20.93bn | $20.63bn | $20.15bn |
Financial ratios
Data as of 7 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 64.0% | 61.9% | 61.0% | 59.8% | 62.6% | 61.0% |
| Operating margin | 19.5% | 22.4% | 20.9% | 16.4% | 15.3% | 15.8% |
| Net margin | 12.9% | 13.2% | 15.4% | 12.8% | 11.7% | 11.1% |
| Return on equity | 14.5% | 14.5% | 17.0% | 14.2% | 13.4% | 12.2% |
| Return on assets | 6.8% | 7.0% | 7.9% | 6.4% | 5.8% | 4.7% |
| Free cash flow yield | 5.0% | 4.3% | 3.7% | 2.8% | 3.3% | 3.3% |
| Revenue growth | 11.2% | 10.2% | 11.1% | 7.8% | 19.2% | -3.6% |
| Earnings growth | 8.5% | -5.4% | 34.2% | 18.3% | 24.7% | -23.2% |
| Current ratio | 1.89x | 1.95x | 1.58x | 1.63x | 2.20x | 1.93x |
| Debt to equity | 0.71x | 0.66x | 0.71x | 0.79x | 0.84x | 1.07x |
| Equity ratio | 46.9% | 48.0% | 46.6% | 45.0% | 43.0% | 38.1% |
| Interest coverage | 8.05x | 12.78x | 12.03x | 8.96x | 7.77x | 7.20x |
| R&D as a share of sales | 6.3% | 6.3% | 6.3% | 6.7% | 6.6% | 6.3% |
| Buybacks as a share of market value | -0.1% | -0.6% | -0.4% | 0.1% | -0.4% | -0.3% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 10.8% | 11.8% | 9.7% |
| Operating income | 9.4% | 10.1% | 8.1% |
| Net income | 11.2% | 15.2% | 8.5% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 63.0% | 61.8% | 61.8% | 62.4% |
| Operating margin | 20.9% | 20.7% | 21.0% | 21.5% |
| Net margin | 13.1% | 13.6% | 13.0% | 13.9% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 41.9 | 46.5 | 36.3 | 39.6 | 51.3 | 58.4 | 38.3 | 16.8 | 57.8 | 27.6 |
| Price to sales | 5.4 | 6.2 | 5.6 | 5.1 | 6.0 | 6.5 | 5.4 | 4.4 | 4.7 | 4.0 |
Market value over time
31 Oct 2016 to 4 Sept 2026, in USD
$43.72bn$117.01bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | -2% | 23% | 22% | -4% | 5% | 12% | 37% | -1% | 30% | 33% |
Dividends and splits
Per share, in the currency the company pays
Paid for 29 years. Last went ex-dividend on 30 Sept 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 2.64 | 3.40 | 3.24 | 3.05 | 2.835 | 2.585 | 2.355 | 2.135 |
- 2-for-1 split · 17 May 2004
- 2-for-1 split · 15 May 2000
- 2-for-1 split · 11 Jun 1996
- 2-for-1 split · 14 Jun 1991
- 1.5-for-1 split · 20 Jun 1989
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.